Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers

European Journal of Clinical Pharmacology

Volumn 63, Issue 7, 2007, Pages 663-668

  Juan, He ^a   Terhaag, Bernd ^b   Cong, Zang ^c   Bi Kui, Zhang ^a   Rong Hua, Zhu ^a   Feng, Wang ^a   Fen Li, Su ^a   Juan, Song ^a   Jing, Tang ^a   Wen Xing, Peng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Arzneimittelwerk Dresden GmbH   (Germany)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Curcumin; P glycoprotein; Pharmacokinetics; Talinolol

Indexed keywords

CURCUMIN; PROPRANOLOL; TALINOLOL; UNCLASSIFIED DRUG; ZHIKEPING;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; DECISION SUPPORT SYSTEM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG USE; ELECTROSPRAY MASS SPECTROMETRY; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VOLUNTEER; WILCOXON SIGNED RANKS TEST;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHINA; COHORT STUDIES; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG THERAPY, COMBINATION; HALF-LIFE; HUMANS; MALE; P-GLYCOPROTEIN; PROPANOLAMINES; RADIATION-SENSITIZING AGENTS;

EID: 34250363135     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0298-0     Document Type: Article

References (54)

1. Campeanu A (2001) The cardiac insufficiency talinolol study (CITAS) study design. Eur J Heart Fail 3:377-380
2. Assmann I (1995) The actions of talinolol, a beta 1-selective beta blocker, in cardiac arrhythmia and acute myocardial infarction. Curr Med Res Opin 13:325-342
3. Maurer HH, Tenberken O, Kratzsch C (2004) Screening for library-assisted identification and fully validated quantification of 22 beta-blockers in blood plasma by liquid chromatography-mass spectrometry with atmospheric pressure chemical ionization. J Chromatogr A 1058:169-181
4. Weigmann I, Terhaag B (1995) Cordanum on target: a beta-blocker time tested and up-to date. Pharmedicum 3:216-220
5. Campeanu A, Olinescu R, Vasile M (1999) Effects of talinolol, a cardioselective betablocker on the oxidative stress in the cigarette smokers. Cardiovasc Drugs Ther 13:68-71
6. Campeanu A, Olinescu R, Vasile M (1999) Effects of talinolol, aβ1-selective betablocker on the oxidative stress in post unstable angina. Cardiovasc Drugs Ther 13:19-23
7. Beate T, Oertel R, Richter K et al (1995) Disposition and bioavailability of theβ1-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos 16:403-414
8. Gramatte T, Oertel R, Terhaag B (1996) Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clin Pharmacol Ther 59:541-549
9. Krueger M, Achenbach H, Terhaag B (2001) Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers. Int J Clin Pharm Ther 39:61-66
10. Ulrike W, Hildegard SL, Ernst M (1996) Evidence for intestinal secretion as an additional clearance pathway of talinolol enatiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res 13:514-522
11. Werner S, Karen L, Georg E (2003) Variability of intestinal expression of p-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets. J Pharm Sci 92:560-566
12. Schwarz UI, Gramatte T, Krappweis J (2000) P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharm Ther 38:161-167
13. Spahn-Langguth H, Langguth P (2001) Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 12:361-367
14. Cascorbi I (2006) Role of pharmocogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112:457-473
15. Sikic BL (1999) Modulation of multidrug resistance: a paradigm for translational clinical research. Oncology 3:183-187
16. Sharom FJ, Yu X, Lu P et al. (1999) Interaction of the p-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in the isolated membranes, reconstituted systems and intact cells. Biochem Pharmacol 58:571-586
17. Motterlini R, Foresti R, Bassi R et al. (2000) Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med 28:1303-1312
18. May LA, Tourkin E, Hoffman SR et al. (2005) Detection and quantitation of curcumin in mouse lung cell cultures by matrix-assisted laser desorption ionization time of flight mass spectrometry. Anal Biochem 337:62-69
19. Shao ZM, Shen ZZ, Liu CH et al. (2002) Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Cancer 98:234-240
20. Anto RJ, Mukhopadhyaya A, Denning K, Aggarwal B (2002) Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 23:143-150
21. Rao CV, Rivenson A, Simi B et al. (1995) Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55:259-266
22. Huang MT, Lou YR, Ma W et al. (1994) Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res 54:5841-5847
23. Shukla Y, Arora A, Taneja P (2002) Antimutagenic potential of curcumin on chromosomal aberrations in Wistar rats. Mutat Res 515:197-202
24. Ikezaki S, Nishikawa A, Furukawa F et al. (2001) Chemopreventive effects of curcumin on glandular stomach carcinogenesis induced by N-methyl-N′- nitro-N-nitrosoguanidine and sodium chloride in rats. Anti-Cancer Res 21:3407-3411
25. Sharma RA, Ireson CR, Verschoyle et al. (2001) Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res 7:1542-1548
26. Ireson C, Orr S, Jones DL, Verschoyle R et al. (2001) Characterization of metabolites of the chemopreventive agent curcumin in humans and rat hepatocytes and in rat plasma and evaluation of their ability to inhibit cyclooxygenase-2 expression. Cancer Res 61:1058-1064
27. Holder GM, Plummer JL, Ryan AJ (1978) The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 8:761-768
28. Wahlstrom B, Blennow G (1978) A study on the fate of curcumin in the rat. Acta Pharm Toxicol 43:86-92
29. Cheng AL, Lin JK, Hsu MM et al. (1998) Phase I chemoprevention clinical trial of curcumin. Proc Am Soc Clin Oncol 17:558a
30. Sharma RA, McLelland HR, Hill KA et al. (2001) Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res 7:1894-1900
31. Limtrakul P, Jorearware W, Anuchapreeda S (1998) The effects of curcumin on the proliferation of cancer cell lines. Chiang Mai Med Bull 38:55-61
32. Mehta K, Pantazis P, McQueen T, Aggarwal BB (1997) Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anti-Cancer Drug 8:470-481
33. Songyot A, Pranee L, Melissa MS (2002) Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64:573-582
34. Limtrakul P, Anuchapreeda S, Buddhasukh D (2004) Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer 4:13-18
35. Limtrakul P, Anuchapreeda S, Lipigorngoson S, Dunn FW (2001) Inhibition of carcinogen induced c-Ha-ras and c-fos proto-oncogenes expression by dietary curcumin. BMC Cancer 1:1-7
36. Rao CV, Rivenson A, Simi B, Reddy BS (1995) Chemoprevention of colon cancer by dietary curcumin. Ann NY Acad Sci 768:201-204
37. Limtrakul P, Lipigorngoson S, Namwong O, Apisariyakul A, Dunn FW (1997) Inhibitory effect of dietary curcumin on skin carcinogenesis in mice. Cancer Lett 116:197-203
38. Werner W, Annika B, Thomas G (2005) The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharm Res 22:728-735
39. Westphal K, Weinbrenner A, Giessmann T (2000) Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 68:345-355
40. Oertel R, Richter K, Gramatte T (1998) Determination of drugs in biological fluids by high-performance liquid chromatography with on-line sample processing. J Chromatogr A 797:203-209
41. Terhaag B, Gramatte T, Richter K (1989) The biliary elimination of the selective beta-receptor blocking drug talinolol in man. Int J Clin Pharmacol Ther Toxicol 27:170-172
42. Lennernas, H, Regardh CG (1993) Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile. Pharm Res 10:879-883
43. Barnwell SG, Laudanski T, Dwyer M (1993) Reduced bioavailability of atenolol in man: the role of bile acids. Int J Pharm 89:245-250
44. Yao H-M, Chiou WL (2006) The complexity of intestinal absorption and exsorption of digoxin in rats. Int J Pharm 322:79-86
45. Schwarz UI, Gramatte T, Krappweis J (2000) P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 38:161-167
46. Schwarz UI, Gramatte T, Krappweis J (1999) Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. Clin Pharmacol Ther 65:283-290
47. 2+ channel antagonists inhibit the intestinal absorption of digoxin in the guinea-pig. Eur J Pharmacol 230:301-305
48. Su SF, Huang JD (1996) Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab Dispos 24:142-147
49. Cvetkovic M, Leake B, Fromm MF (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871
50. Spahn-langguth H, Baktir G, Radschuweit A (1998) P-glycoprotein transporters and the gastrointestinal tract: evaluation of thepotential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 36:16-24
51. Asai A, Miyazawa T (2000) Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci 67:2785-2793
52. Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, Lin JK (1997) Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 15:1867-1876
53. Srinivas RV, Middlemas D, Flynn P (1998) Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 42:3157-3162
54. Gutmann H, Fricker G, Drewe J (1999) nteractions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 56:383-389